RxDoctor Payments Data

Catherine Marando, MD

Ophthalmology · Concord, NHNPI 1336678119

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 61.6% of it on its own, with 4 other manufacturers making up the rest. That places this record below the midpoint for ophthalmology clinicians in NH, where the typical reported total is $750.

$288in general payments, 2019–2025

Across 12 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$177
  • AbbVie$47
  • Glaukos Corporation$25
  • Sight Sciences, Inc.$24
  • Bausch & Lomb Americas Inc.$15

What the payments were for

  • Food & beverage$288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$288 in reported general payments places this provider in the 30th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$396,211
Medicare patients
743
Services billed
3,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate200$133,429
VyzultaLatanoprostene Bunod71$45,478
LumiganBimatoprost58$37,983
RocklatanNetarsudil Mesylat/Latanoprost50$28,843
ProlensaBromfenac Sodium46$22,898
Latanoprost1,301$14,581
Brimonidine Tartrate524$10,047
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat559$9,867
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol69$8,516
Prednisolone Acetate252$8,401
CombiganBrimonidine Tartrate/Timolol25$7,985
SimbrinzaBrinzolamide/Brimonidine Tart24$7,649
Alphagan PBrimonidine Tartrate17$7,206
Timolol Maleate520$5,656
Brinzolamide23$4,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$47$53,174100 claims
Bausch & Lomb Americas Inc.Vyzulta$15$45,47871 claims
AlconSimbrinza$177$7,64924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →